Avience Biomedicals IPO Day 1: GMP ₹60

Alright folks, let’s dive into the very first day of the Avience Biomedicals SME IPO on the NSE. The subscription window opened today, June 18th, 2026, and it’s been a quiet start, to say the least. With the IPO period set to run until June 22nd, there’s still plenty of time for things to heat up. For now, Day 1 has registered zero subscriptions across all categories – Retail, NII, and QIB. This isn’t unusual for the opening day, especially for SME IPOs, but it’s certainly something we’ll be watching closely as the week progresses. The issue price is fixed at ₹196 per share, and the lot size is 600 shares, meaning a single lot application will cost ₹117,600.

Subscription Status

As of the end of Day 1, the subscription numbers are showing a flat 0x across the board. This means no applications have been filed yet by Retail Individual Investors (RIIs), Non-Institutional Investors (NIIs), or Qualified Institutional Buyers (QIBs). For an SME IPO, a zero subscription on Day 1 is pretty standard. Many investors, particularly the larger ones like NIIs and QIBs, prefer to wait and see the momentum build before putting their money in. They often assess market sentiment and the subscription levels in the final days. Retail investors, while often quicker to act, might also be observing the initial response. The lack of early subscription doesn’t necessarily spell doom; it simply indicates a cautious beginning. We’ll need to see how the subscription picks up over the next few days.

GMP Update

Now, let’s talk Grey Market Premium (GMP). The current GMP for Avience Biomedicals is standing firm at ₹60. Interestingly, this is the same as yesterday’s GMP, which was also ₹60. This stability in GMP, even with zero subscriptions on Day 1, is a positive sign. It suggests that the market sentiment for Avience Biomedicals remains robust, and there’s a consistent demand at this premium level. With an issue price of ₹196, a GMP of ₹60 translates to an expected listing price of around ₹256 (₹196 + ₹60). This ₹256 per share estimate is what’s driving interest and maintaining the GMP. The fact that it hasn’t dipped despite the slow start on the subscription front is encouraging.

Should You Apply?

So, the big question: should you throw your hat in the ring for Avience Biomedicals? It’s a balanced picture right now. On one hand, the GMP is stable and healthy, hinting at a potential listing gain. The expected listing price of ₹256 offers a decent upside from the issue price of ₹196. On the other hand, the subscription has been non-existent so far. That said, it’s only Day 1, and SME IPOs often see a surge in the last couple of days. If you’re an investor looking for potential short-term gains and are comfortable with the inherent risks of SME IPOs, the current GMP might tempt you. However, it’s always wise to remember the SEBI advisor’s caution: “Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.” Do your own due diligence, assess your risk appetite, and consider how the subscription numbers evolve over the next few days.

For more in-depth analysis and all the latest updates on the Avience Biomedicals IPO, you can View Full Avience Biomedicals IPO Details.